Capital One National Association Increases Stake in Gilead Sciences (GILD); As At&T (T) Stock Declined, Ramsay Stattman Vela & Price Increased Its Position

June 15, 2018 - By Adrian Erickson

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Ramsay Stattman Vela & Price Inc increased its stake in At&T Inc. (T) by 9.01% based on its latest 2018Q1 regulatory filing with the SEC. Ramsay Stattman Vela & Price Inc bought 8,870 shares as the company’s stock declined 13.21% with the market. The institutional investor held 107,321 shares of the telecommunications equipment company at the end of 2018Q1, valued at $3.83M, up from 98,451 at the end of the previous reported quarter. Ramsay Stattman Vela & Price Inc who had been investing in At&T Inc. for a number of months, seems to be bullish on the $202.99B market cap company. The stock increased 1.65% or $0.535 during the last trading session, reaching $33.055. About 59.55M shares traded or 77.36% up from the average. AT&T Inc. (NYSE:T) has declined 14.96% since June 15, 2017 and is downtrending. It has underperformed by 27.53% the S&P500. Some Historical T News: 22/03/2018 – AT&T may be better off losing Time Warner and not relying on the dying pay-TV model; 16/04/2018 – A SHAME AT&T, TELEFONICA NOT INVESTING IN MEXICO: SLIM; 23/04/2018 – AT&T Bond Trading 5x Average; Clients Net Buyers; 22/03/2018 – Cox Executive Warns of ‘Ugly’ Outcome If AT&T Merger Is Approved; 07/03/2018 – AT&T Files for Potential IPO of Vrio Corp. Holding Company for DIRECTV Latin Americ; 05/03/2018 – MOODY’S: TAX OVERHAUL WILL BOOST CASH FLOWS FOR AT&T & VERIZON; 15/05/2018 – AT&T INC – EXPECTS A RULING ON JUNE 12 IN SUIT BROUGHT AGAINST CO, TIME WARNER BY U.S. DEPARTMENT OF JUSTICE; 13/03/2018 – TWX, T: Latest twist in DOJ-AT&T case: The government does want AT&T to submit its arbitration offer as evidence. – ! $TWX $T; 03/04/2018 – Tower One Wireless Acquires Mexico Tower Company With AT&T Master Lease Agreement; 11/04/2018 – AT&T INC – IN ADDITION TO MACRO SITES, NEW DEAL COVERS SMALL CELL DEPLOYMENTS

Capital One National Association increased its stake in Gilead Sciences Inc (GILD) by 91.61% based on its latest 2018Q1 regulatory filing with the SEC. Capital One National Association bought 15,232 shares as the company’s stock declined 17.62% with the market. The institutional investor held 31,859 shares of the health care company at the end of 2018Q1, valued at $2.40 million, up from 16,627 at the end of the previous reported quarter. Capital One National Association who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $91.02B market cap company. The stock decreased 1.61% or $1.149 during the last trading session, reaching $70.001. About 5.35M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 15, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 12/03/2018 – Gilead Sciences Names Andrew Cheng Chief Medical Officer; 05/03/2018 – GLAXOSMITHKLINE STUDIED DOLUTEGRAVIR IN HIV, TUBERCULOSIS; 06/03/2018 – Top 3 — #1 Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD; 30/05/2018 – GILEAD, GALAPAGOS REPORT RESULTS W/ FILGOTINIB IN EQUATOR STUDY; 21/05/2018 – Gilead’s Odefsey Falls After 1-Wk Rise, Triumeq Declines: HIV; 23/05/2018 – Startup Headed by Gilead Ex-Partner Lures Away Its Top Scientist; 18/05/2018 – EU warns of possible birth defect link to GSK’s HIV drug; 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 15/05/2018 – GILEAD: FDA APPROVED TRUVADA IN ADOLESCENTS; 01/05/2018 – Clock Ticks for Gilead as Revenue, Earnings Per Share Fall Short

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” on May 30, 2018, also Seekingalpha.com with their article: “Gilead’s Evolution In Oncology, With Comments On Valuation” published on June 07, 2018, Seekingalpha.com published: “Gilead: Novartis’s Kymriah Is Coming To America” on May 24, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Growth Pick For Your Portfolio” published on June 15, 2018 as well as Fool.com‘s news article titled: “Has the Gilead Sciences Buy Argument Collapsed?” with publication date: June 01, 2018.

Since January 2, 2018, it had 0 buys, and 23 sales for $48.21 million activity. Cogan John Francis sold $472,065 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, March 12. $1.18M worth of stock was sold by Alton Gregg H on Tuesday, February 20. The insider WILSON GAYLE E sold 60,000 shares worth $4.68M. Another trade for 5,000 shares valued at $401,566 was made by Washington Robin L on Wednesday, February 21. 100,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $8.02M were sold by Meyers James R.

Capital One National Association, which manages about $1.43 billion US Long portfolio, decreased its stake in Landstar Sys Inc (NASDAQ:LSTR) by 3,518 shares to 96,593 shares, valued at $10.59M in 2018Q1, according to the filing. It also reduced its holding in Cna Finl Corp (NYSE:CNA) by 6,408 shares in the quarter, leaving it with 151,145 shares, and cut its stake in T Mobile Us Inc (NYSE:TMUS).

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was initiated by Berenberg with “Buy” on Monday, September 12. The firm earned “Hold” rating on Friday, July 29 by Argus Research. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, July 29 by Oppenheimer. The rating was upgraded by Argus Research on Thursday, August 31 to “Buy”. The firm has “Mkt Perform” rating given on Tuesday, September 27 by Leerink Swann. PiperJaffray reinitiated Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, May 31 with “Overweight” rating. The rating was initiated by Stifel Nicolaus on Monday, November 14 with “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, February 3 by RBC Capital Markets. Barclays Capital maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, March 6. Barclays Capital has “Overweight” rating and $95 target. The firm has “Buy” rating given on Friday, February 12 by Maxim Group.

Investors sentiment increased to 0.88 in Q1 2018. Its up 0.08, from 0.8 in 2017Q4. It is positive, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Loring Wolcott & Coolidge Fiduciary Advsrs Ltd Liability Partnership Ma holds 375,401 shares or 0.51% of its portfolio. South Dakota Inv Council owns 817,059 shares for 1.41% of their portfolio. Swiss Financial Bank invested 0.4% in Gilead Sciences, Inc. (NASDAQ:GILD). Cubist Systematic Strategies Llc invested in 0.08% or 17,215 shares. Spinnaker Tru holds 2,831 shares or 0.02% of its portfolio. Brown Brothers Harriman And holds 0.01% or 15,551 shares in its portfolio. Masters Cap Mgmt Ltd Liability Corp reported 200,000 shares. 759,706 are owned by State Of Tennessee Treasury Department. Norinchukin Natl Bank The holds 187,812 shares. Hillsdale Investment stated it has 5,310 shares. Quantres Asset Mgmt invested 0.79% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cincinnati Finance, Ohio-based fund reported 938,419 shares. Greenwich Wealth Limited Liability Corp, a Connecticut-based fund reported 8,428 shares. Verition Fund Ltd invested in 0.05% or 8,357 shares. Sentry Investments invested in 0.37% or 332,195 shares.

Among 33 analysts covering AT&T Inc. (NYSE:T), 13 have Buy rating, 2 Sell and 18 Hold. Therefore 39% are positive. AT&T Inc. had 86 analyst reports since July 27, 2015 according to SRatingsIntel. Moffet Nathanson downgraded AT&T Inc. (NYSE:T) rating on Friday, April 1. Moffet Nathanson has “Sell” rating and $35 target. Scotia Capital maintained the stock with “Hold” rating in Tuesday, January 30 report. On Monday, December 12 the stock rating was upgraded by Robert W. Baird to “Outperform”. The stock of AT&T Inc. (NYSE:T) earned “Outperform” rating by Oppenheimer on Saturday, September 5. The firm has “Hold” rating by Drexel Hamilton given on Monday, October 24. On Monday, September 26 the stock rating was upgraded by HSBC to “Hold”. Bank of America maintained it with “Neutral” rating and $40 target in Friday, February 2 report. The stock of AT&T Inc. (NYSE:T) earned “Hold” rating by Deutsche Bank on Wednesday, January 11. KeyBanc Capital Markets maintained the stock with “Hold” rating in Wednesday, October 11 report. Deutsche Bank maintained AT&T Inc. (NYSE:T) rating on Wednesday, October 25. Deutsche Bank has “Hold” rating and $38 target.

More notable recent AT&T Inc. (NYSE:T) news were published by: Seekingalpha.com which released: “Market Is Revaluing Entertainment Stocks – Cramer’s Mad Money (6/14/18)” on June 15, 2018, also Seekingalpha.com with their article: “Retirement Strategies: Time For AT&T?” published on June 07, 2018, Fool.com published: “Comcast Makes an Offer That’s Hard to Refuse” on June 15, 2018. More interesting news about AT&T Inc. (NYSE:T) were released by: Seekingalpha.com and their article: “AT&T: The Clock Is Ticking” published on May 30, 2018 as well as Seekingalpha.com‘s news article titled: “AT&T: Ignore The Noise, Follow The Fundamentals” with publication date: June 09, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>